The biotechnology industry is a core component of modern innovation. It has experienced significant growth recently, largely driven by groundbreaking research and growing global health needs. The global biotechnology market size was valued at $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96 percent from 2024 to 2030. Some of the key drivers in this growth are advancements in genetic engineering, a growing demand for personalized medicine, and the rise of cell and gene therapies. Governments and private entities are investing heavily in biotech research, signaling confidence in biotech’s potential to address important health and environmental challenges.
AI and Big Data: Transforming Biotech Research
Biotechnology has expanded across industries, and artificial intelligence (AI) is playing a pivotal role in drug discovery and development. According to McKinsey, integrating AI into biopharmaceutical research could save companies billions in development costs while shortening the time to market for new treatments. Companies are leveraging big data to analyze patient populations, predict drug efficacy, and streamline clinical trials. This data-driven approach enhances efficiency and reduces risks, positioning biotech firms to deliver more effective solutions to unmet medical needs.
The biotech industry is also addressing global health inequities by developing accessible and scalable solutions. The pandemic highlighted the importance of biotechnological advances, from mRNA vaccines to rapid diagnostic tools. The lessons learned have spurred efforts to build more resilient health systems and equitable access to biotechnological innovations worldwide. With a growing emphasis on sustainability, the industry is also spearheading initiatives in bio-based materials and renewable energy.
NeOnc Technologies: Advancing Brain Cancer Treatment
NeOnc Technologies is combining scientific innovation with strategic business practices in this bustling industry. The company exemplifies how biotech firms can potentially translate research into impactful solutions. Founded by Dr. Thomas Chen, a leading neurosurgeon and a professor at USC, NeOnc’s innovative approach to drug delivery and its focus on each patient demonstrates how targeted strategies can potentially lead to meaningful advancements in healthcare.
NeOnc Technologies is developing a non-invasive nasal delivery system for brain cancer drugs, addressing one of the most significant challenges in treating neurological conditions: the blood-brain barrier. This physiological barrier has historically limited the effectiveness of many treatments by restricting drug delivery to the brain. NeOnc’s system is under development to bypass this barrier, with the potential of delivering drugs directly to the target area via nasal inhalation. The approach has shown promising results in clinical trials.
“One of our problems is just getting the drug or the biological to the cancer. We have in our brain something called a blood-brain barrier… It’s used to keep various pathogens and compounds away from the brain. But in the case of brain cancer, where the disease is in the brain, we’re trying to get drugs or other biologics to the target, and the blood-brain barrier is preventing that,” explains Dr. Chen.
NEO 100: A Novel Approach to Brain Cancer Treatment
The company’s lead compound, NEO 100, is derived from perillyl alcohol, a natural compound. Designed to target brain tumors in patients with IDH1/2 mutations, the drug is currently being evaluated in phase 2A trials involving 25 participants. Initial results have been encouraging. A phase 2B trial involving 60 patients may follow, potentially paving the way for FDA approval. In parallel, NeOnc is exploring a pediatric version of the treatment currently in phase 1 trials.
“In our brain, we have 12 cranial nerves. The first cranial nerve is called the olfactory nerve… It’s very effective for delivering different substances to the brain,” says Dr. Chen. “What we’re doing now is that we’re taking our compound and having the patient inhale the treatment. It goes directly from the olfactory nerve, gets circulated via the spinal fluid, and into the brain tumor.”
NeOnc Technologies’ achievements extend beyond clinical innovation. The company holds 135 patents worldwide. By maintaining a robust intellectual property strategy, NeOnc’s goal is to ensure that its treatments remain at the cutting edge of brain cancer therapy.
Strategic Growth and the Future of NeOnc Technologies
Strategic business decisions have been integral to NeOnc’s growth. The company initially planned a traditional IPO, seeking to raise $50-75 million to fund its operations. However, market conditions prompted a shift in strategy, and NeOnc now plans a direct listing IPO. This less conventional approach reflects the company’s adaptability and confidence in its value proposition. A direct listing allows NeOnc to reach public markets while minimizing dilution for existing shareholders, positioning the company for sustainable growth. NeOnc’s approach serves as a blueprint for success in the biotech sector, demonstrating how strategic alignment of science, business, and patient needs can drive meaningful progress.
Kyle Lewis is a seasoned technology journalist with over a decade of experience covering the latest innovations and trends in the tech industry. With a deep passion for all things digital, he has built a reputation for delivering insightful analysis and thought-provoking commentary on everything from cutting-edge consumer electronics to groundbreaking enterprise solutions.
